8.51
Chimerix Inc (CMRX) 最新ニュース
11 Best Performing NASDAQ Stocks So Far in 2025 - Insider Monkey
Exploring US High Growth Tech Stocks In March 2025 - simplywall.st
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo Finance
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Chimerix: Q4 Earnings Snapshot -March 21, 2025 at 06:07 am EDT - MarketScreener
Chimerix Reports Earnings as $935M Jazz Buyout and FDA Drug Review Advance - StockTitan
Investment Analysts’ Recent Ratings Updates for Chimerix (CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $8.47 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.47 - Investing.com India
Ireland: Jazz adds to oncology pipeline with Chimerix - Investors in Healthcare
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Finansavisen
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - Financial Content
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire
Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
Chimerix Expands Team with Strategic New Hire, Offers 70K Share Options Package - StockTitan
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair - Bluefield Daily Telegraph
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - GlobeNewswire
HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Top Medical Stocks To Add to Your Watchlist – March 5th - Defense World
Jefferies Financial Group Reaffirms Hold Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Best Pharmaceutical Stocks To Watch Today – March 5th - Defense World
Wedbush Reaffirms “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - TradingView
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Chimerix downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga India
Jazz Pharmaceuticals to acquire Chimerix for $935m - World Pharmaceutical Frontiers
Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN
Jazz Pharmaceuticals bids for Chimerix in $935m deal - MSN
CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz - MSN
Jazz to Acquire Chimerix for $935M, Expanding Rare Oncology Portfolio - Genetic Engineering & Biotechnology News
Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada
Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld MedTech
大文字化:
|
ボリューム (24 時間):